Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Core Insights - Coya Therapeutics, Inc. released positive results from a Phase 2 trial of low-dose interleukin-2 (LD IL-2) for patients with mild to moderate Alzheimer's Disease, demonstrating safety and tolerability [1][2] - The treatment showed significant improvements in cerebrospinal fluid (CSF) soluble Aβ42 levels, indicating targeted biological activity [2] - The q4wks dosing regimen resulted in a clinically meaningful improvement in cognitive function compared to placebo, while the q2wks group did not show similar benefits [3] Group 1 - The Phase 2 trial met its primary and secondary endpoints, confirming the safety and tolerability of LD IL-2 in Alzheimer's patients [1] - The q4wks regimen led to a 27% slower decline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) scores compared to the placebo group [3] - The ADAS-Cog14 scores showed a slight improvement of 4.93 points (P=0.061) in the q4wks group compared to placebo, while the q2wks group did not demonstrate cognitive benefits [3] Group 2 - The company plans to advance the q4wks dosing regimen for further development [3] - Coya Therapeutics has seen a 70% increase in stock price since its IPO, indicating strong market interest [2] - Despite positive trial results, COYA stock experienced a decline of 31.4% to $6.982 following the announcement [4]